Rhythm Biosciences (ASX:RHY) announces gastric cancer diagnostic test update

Rhythm Biosciences Ltd (ASX:RHY) has identified protein biomarker combinations that effectively differentiate between blood samples from cancer patients and those from healthy controls. The company aims to develop a gastric cancer clinical diagnostic assay with >75% sensitivity and >90% specificity, providing a potential breakthrough in early detection of gastric cancer.

Executive Commentary on Gastric Cancer Diagnostic Test Update

The Company is pleased to announce the progress made in the expansion of our cancer diagnostics technology platform, particularly in the field of gastric cancer. Our comprehensive analytical data has identified informative subsets of protein biomarkers with the potential to be developed into a gastric cancer clinical diagnostic assay. The effective biomarker combinations we have identified demonstrate promising sensitivities and specificities, which could significantly impact the early detection of gastric cancer. We are committed to further developing and validating this potential gastric cancer assay to provide a commercially scalable, proprietary blood test for early detection, ultimately improving patient outcomes and reducing the global burden of cancer.

Summary of Rhythm Biosciences' Gastric Cancer Diagnostic Test Update

Rhythm Biosciences (ASX:RHY) has made significant progress in the expansion of its cancer diagnostics technology platform, specifically in the area of gastric cancer. The company has identified protein biomarker combinations that effectively differentiate between blood samples from cancer patients and healthy controls, with sensitivities >75% and specificities >90%. This development holds the potential to revolutionize the early detection of gastric cancer, a disease with poor outcomes and a high prevalence in certain geographic regions. Rhythm Biosciences aims to develop a commercially scalable, proprietary blood test for early detection, aligning with its commitment to improving patient outcomes and reducing the global burden of cancer.